Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Acta Biomed ; 87(3): 314-317, 2016 01 16.
Article in English | MEDLINE | ID: mdl-28112700

ABSTRACT

Solitary fibrous pleura tumor is a rare primary intrathoracic tumor of the pleura. It usually has an indolent clinical course, but sometimes it can have an aggressive behaviour. In 1930 Doege and Potter independently described this neoplasm, presenting with symptoms of hypoglycemia, hence the eponim of Doege-Potter's Syndrome. In this report, we illustrate a case of Doege Potter's Syndrome, treated with complete surgical resection.


Subject(s)
Hypoglycemia/etiology , Solitary Fibrous Tumor, Pleural/complications , Aged , Humans , Male , Severity of Illness Index , Solitary Fibrous Tumor, Pleural/pathology , Solitary Fibrous Tumor, Pleural/surgery , Syndrome
2.
Nutr Metab Cardiovasc Dis ; 11(3): 168-75, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11590992

ABSTRACT

BACKGROUND AND AIM: While lispro insulin has been reported to lower postprandial blood glucose concentrations, less consistent effects have been shown for glycosylated hemoglobin (HbA1c) levels. Aim of this study was to determine whether pre-meal association of NPH, an intermediate-acting insulin, with lispro improves overall glycemic control in type 1 diabetic patients. METHODS AND RESULTS: Eighty-five type 1 diabetic patients were studied in a multicenter randomized comparative (human regular vs lispro insulin) crossover (3-month) study in which NPH insulin was given as a dinner or bedtime injection and at breakfast and lunch if necessary. The number of injections was kept constant: 42% and 58% of patients injected insulin 3 and 4 times per day, respectively. Fasting and preprandial blood glucose levels were similar, while postprandial levels improved after lispro compared to human regular insulin (breakfast: 8.28 +/- 2.39 vs 9.28 +/- 2.72 mmol/l; lunch: 8.33 +/- 2.67 vs 9.06 +/- 2.67 mmol/l, dinner: 8.06 +/- 2.72 vs 9.28 +/- 2.44 mmol/l, ANOVA: p = 0.003). HbA1c also improved after lispro: 8.1 +/- 0.9 vs 8.3 +/- 0.8%, p < 0.05. The rate of hypoglycemia was similar. Patients showed better acceptance of lispro treatment (p < 0.001). CONCLUSIONS: Lispro improves overall blood glucose control in type 1 diabetic patients without increasing the incidence of hypoglycemia. This can be achieved by an optimal combination of lispro insulin with NPH whenever the time intervals between meals are too long.


Subject(s)
Blood Glucose/drug effects , Diabetes Mellitus, Type 1/drug therapy , Hypoglycemic Agents/therapeutic use , Insulin, Isophane/therapeutic use , Insulin/analogs & derivatives , Insulin/therapeutic use , Adolescent , Adult , Blood Pressure/physiology , Body Weight/physiology , Cross-Over Studies , Diabetes Mellitus, Type 1/physiopathology , Female , Humans , Insulin Lispro , Lipids/blood , Male , Middle Aged , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...